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l uring the p~st 30 years orthotopic liver transplantation Eli~uF h.as become a hIghly successful form of therapy,I-7 and as of thIS wrIt-
ing it is being performed at more than 100 institutions in the U.S., 
and a similar number in Europe. This is testimony to the great advances 
achieved in this field since the 1960s and 1970s, when there were essen-
tially only two places actively engaged in liver transplantation.3,8 
Essential to its success have been the technical refinements intro-
duced during the last three decades,7,9 which have allowed many sur-
geons around the world to be able to do the procedure safely. Liver 
transplantation is still considered as one of the most complex opera-
tions, and therefore the margin of error is small and attention to tech-
nical detail is crucial to a satisfactory outcome. This is magnified in 
importance since OLTx, unlike kidney, heart, pancreas and intestinal 
transplantation, lacks a back-up system, such as dialysis, ventricular 
assist device, insulin or total parenteral nutrition. Thus, the smallest 
mistake in the surgical management of the patient may prove fatal. 
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In this chapter we will describe four 
major clinical advances in the field of 
liver transplantation, achieved between 
1989 and 1994 at the Pittsburgh 
Transplantation Institute. First was the 
introduction. of the novel immunosup-
pressive drug FKS06, which after 
extensive in vitro and in vivo studies was 
approved by the Food and Drug 
Administration on April 8, 1994, and is 
now available for clinical use in the U.S. 
Second, the feasibility of combined 
liver-intestinal and multivisceral trans-
plantation as a surgical treatment for 
patients with simultaneous liver and 
intestinal failure. Third, the definition 
of the biological basis of clinical liver 
xenotransplantation, as well as the 
strategies for future investigations. 
Fourth, the attempts to induce graft 
acceptance (donor-specific nonreactivi-
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ty) by cell augmentation with simulta-
neous donor bone marrow infusion. 
Each of these four advances will be 
examined and discussed separately here-
in. Data are presented as the mean ± SD. 
Survival curves for both patients and 
grafts were estimated by the Kaplan-
Meier method, and the comparison 
among the different cohorts within each 
population was done by a generalized 
Wilcoxon (Breslow) test. 
FOUR YEARS EXPERIENCE WITH FK5D6 
IN LIVER TRANSPLANTATION 
FKS06 (tacrolimus, Prograf®), the 
first baseline immunosuppressive drug to 
be certified by the FDA in 11 years, 
became available in pharmacies in the 
United States on June 1, 1994. Followin§ 
3 years of preclinical research in Chiba,' -
n 
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Table 1: Indications for primalY liver bHspIantation with FK506 as the primalY immunosuppressive 
acent. at tile PIttsburgh Transplantation Institute. 
Nonrandomized Randomized 
(n=533) (n=79) 
n (%) n (%) 
Number 01 patients 
Adults 429 79 
Children 104 0 
OLTxll 70 5 
OLTx III 6 0 
Number 01 Grafts 615 84 
liver Disease 
Nonalcoholic cirrhosis 15 (28) 27 (34) 
Alcoholic cirrhosis 92 (17) 28 (35) 
Autoimmune disorders 78 (15) 17 (22) 
Biliary atresia 59 (11) 2 (3) 
Genetic disorders 14 (3) 1 (1) 
Tumor 55 (10) o (0) 
Fulminant failure 23 (4) o (0) 
Others 61 (12) 4 (5) 
TIllIe 2: CIaic8I ...... of the ............... -.....domImd patieIIIs who ........... prinuuy liver 
11' ...... W- hIInIIIy 19, 1990 .... DIamber 21, 1991 under FKS06 rrracalilnus, ......,-). 
376 
I; Pittsburgh, 16-21 Cambridge,22 24 and 
elsewhere, the drug was first used clini-
cally in our center in February, 1989, to 
suc'cessfully treat patients who were 
undergoing intractable rejection of their 
liver allografts despite maximum 
cyclosporine-based therapy.25 A few 
months later, extensiye trials were begun 
with FKS06 as the primary immunosur 
pressant, for recipients of all of the con 
monly transplanted organs. 26 ,27 We 
report here our experience in 1,153 con-
secutive patients who underwent primary 
liver allografts under FKS06 therapy. The 
biological effects of this agent, its phar-
macokinetics, and assay methods are fully 
described e1sewhere. 2832 
PATIENTS AND METHODS 
From August 18,1989, through 
August I, 1993, 1,153 consecutive 
patients underwent primary OLTx at the 
Pittsburgh Transplantation Institute, . -d 
received FK506 as the primary immUl <0-
suppressive agent. Of these, 971 (84%) 
were adults, while 182 (16%) were chil-
dren. The mean age was 51 ± 12 years 
(range: 18-76) for adults and 6 ± 6 years 
(range: 0.2-17.8) for children. Among 
the adults, 2S 1 (26%) were over 60 
years of age. Table 1 lists the indication 
for OLTx, based upon the final patho-
logical diagnosis of the ex planted liver. 
Retransplantation was required in 138 
(12%) patients; 122 had a second trans-
plant, 1 S had a third transplant, and one 
had 4 grafts. The survival analyses were 
based on follow-up until October, 19~PI 
There were 612 patients transplanted 
between February 19, 1990 and 
December 21, 1991. Seventy-nine 
patients were part of a randomized trial 
that was conducted during that period. 
comparing cyclosporine to FKS06, while 
the remaining S33 patients were excluded 
from randomization. The criteria for 
exclusion were: age < 18 or > 60, posi-
tive HBsAg, malignancy, multiple organ 
transplantation, renal failure, active infec-
tion, coma, significant heart or lung dis- . 
ease, previous hepatobiliary and/ or portal . 
hypertension surgery, unsatisf:,ctory 
recipient operation, and liver alk,:raft Of 
uncertain quality. 13 The differenceS 
between the randomized and non ran-
domized patients are summarized in Table 
2. The initial phase of the study was car-' 
ried out during our early learning curve. 
in which the daily induction doses 
two or three times greater than those 
rently recommended. 3o,34-36 Our 
policy is to give FKS06 initially as a 
I 
l 
Tal 
tra 
PI'CI 
tinuous intravenous infusion over 24 
hours, at a dose of 0.05 mg/kg. The con-
version from intravenous to oral therapy 
is usually made without any overlap, with 
a starting oral dose of 0.1 to 0.15 mg/kg 
twice a dav. Dose adjustments were made 
in the pre~ence of rejection, adverse drug 
reactions (with special emphasis on 
nephrotoxicity and neurotoxicity), infec-
tion, and according to the functional sta-
tus of the graft, l+ and always with close 
attention to the plasma trough levels. 
One gram of methylprednisolone was 
invariably administered intravenously 
immediately after graft reperfusion. 
Patients were then placed on 20 mg of 
prednisone daily and, in the absence of 
rejection, the dose was gradually 
reduced over several weeks. Quite fre-
quently, the prednisone was eventually 
stopped altogether. The first 58 patients, 
and those who had a strong positive 
cytotoxic crossmatch, were given a 5-
day methylprednisolone taper, starting at 
200 mg/ day on the first postoperative 
day and reaching 20 mg/ day by the sixth 
postoperative day. Steroid doses were 
scaled down appropriate!y in children. 
Prostaglandin E1 (ProstinQ\) was added to 
the immunosuppressive cocktail of some 
patients during the first postoperative 
week (37). Also, a low dose of azathio-
prine (0.5-2 mg/Kg/day) was given to 
about 10% of the patients at some time 
during the postoperative period. 38 
If rejection was documented it was 
treated with an increase in the mainte-
nance dose of FK506, and a one gram 
holus of either methylprednisolone or 
,,·drocortisone. A steroid recvcle and/ or, 
f~ore rarely, a 5-day course ~f OKT3 (5-
10 mg/ day) was given to patients with 
moderate to severe rejection episodes. 
RESULTS 
With a mean follow-up of 22 ± 15 
months (range: 3-49 months), the over-
CAUSES n (%) 
Infections 99/1,153 (9) 
Graft Failure 24/1,153 (2) 
\Ialignancy 21/1,153 (2) 
Cardiovascular 18/1,153 (1 ) 
Others 46/1,153 (4) 
Unknown 25/1,153 (2) 
TOTAL 233/1,153 (20) 
Table 3: Causes of death after primary liyer 
transplantation under FK 506 (Tracolimus, 
Prograp). 
all actuarial patient survival rates were 
90%, 87%, 83%, and 75% at 3, 6, 12 
and 48 months, respectively (Figure 1). 
Out of the 1,153 OLTx recipients, 233 
(20%) died for various reasons, which 
are listed in Table 3. The total allografts 
were 1,308 and 155 (13%) were 
replaced. However, rejection was the 
cause of failure for only 6 grafts. The 
overall graft survival was 81 %, 78%, 
74%, and 65% at 3,6, 12, and 48 
months, respectively (Figure 1). 
As expected, the highly selected ran-
TI'G..,.,GDkltion 
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do~ized group had significantly better 
patient (p=O.OO6) and graft (p=O.OOI) 
survivals than the non-randomized group 
(Figure 2). The 2-year patient survivals 
were 91 % and 76%, with graft survivals 
of 88% and 67%, for the randomized and 
non-randomized groups, respectively. 
The survival differences reflect the cumu-
lative detrimental effects of the exclusion 
criteria that were used for randomization. 
Patients suffering from either parenchy-
mal or cholestatic liver pathology had 
high long-term survival rates with our 
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F"tgUre 1: Kaplan-Meier actuarial patient and allograft suniYal for primary liver transplant recipients who 
received FKS06 as the primary immunosuppressive agent, at the Plttsllurgh Transplantation Institute, 
between August 8, 1989 and August 1, 1993. (From: Abu-EIma&d K, Bronsther 0, Jain A, Irish W, Fung JJ, 
Ramos H, Marino IR, Dodson F, Selby R, Doyle H, FIII'IIkawa H, GaJowski T, Hour 8, Reyes J, Pi .... A, Reo 
A, Fontes P, CasnIIIa A, Jabbour N, Marsh W, Talds A, Todo S, hndsuld S, Stant 1E. Recent adYanceI in 
hepatic transplantation at the University of Pittsburgh. In: ''Clinical Transplants, 1993" Terasaid P.I., ed., 
137·152, published by UCLA TISSU8 Typing Laboratory, 1000 Veterans Avenue, Los Angeles, California, 
90024. Used by peillission). 
iii 
> 60 K~ 
::J 
(/) 40 
c: 
.!!! 
i\i 20 
a.. 
•• - Randomized (n.79) 
- Nonrandomized (n.S33) 
o+--r--,-...---.---r-,..---r--, 
o 6 12 18 24 30 36 42 48 
Months After Orthotopic Liver 
Transplantation 
100 
~ 80 
L 
~ 60 
K~ 
::J (/) 40 
~ 
5 20 
--f~- -. ----m-K~~I~--·--- ---
.... RandomIzed (n.84) 
_ Nonrandomlud (n.615) 
o+-K-~~~~-r-r-r­
o 6 12 18 24 30 36 42 48 
Months After OrthotopiC Liver 
Transplantation 
F"cure 2: Kaplan-Meier acIuariaI paIIenllleftJ and aIIapIIft 1.-0 sunIYaI for....., wi • Ilf "'-r 
plant recipienIs which _ transpIInIed dIaing the tInIe 01 the ...... 1iIId ....., ......, s-.. 
19911. IFrom: Abu-EInII&d K, Bransther 0, Jain A, IItIh W, FIIIII II, ..... H, =.. ~ ...... 
Doyle H, FIInIkawa H, ~ T, NoIr II, .". J, PInna A, Rao ~ p'. • ... at ............. 
W Tzalds A, Todo S, IwaIsuId S, Sterzl TE. Recent adYancIS In - I UClA _ ~ In: "Clinical Trwilfllanb, 1993" Terauld PJ., ..... 137-15Z, ~ ~ ,__,: 
LabonIIoIy, 1000 v .... Awnue, Los ..... CaIfamIa, 10024. UllllliII1 pc • 
377 
The Lilrat Am-ill U"u Trall.plantation at till' Pirrsburgh Transplantation InrtituU 
MARINO. DOYLIl, ABU-ELMAGD, SCOITI-FOGLIENI, MANEZ, TZAKIS, TODO, FUNG, STARZL 
immunosuppressive protocol based on 
FK506, as clearly shown in Figure 3. The 
need for retransplantation was Significant-
ly reduced, being only 12%, and the 
actuarial patient survival after retrans-
plantation was 75% at 3 months and 54% 
and at 2 years. We attribute the high sur-
vival rate (82% at 12 months) in patients 
undergoing OLTx for fulminant hepatic 
failure to our current policy of intensive 
monitoring of intracerebral blood flow 
and intracranial pressure, with interven-
tions aimed at maintaining intracranial 
pressure within normal limits, in addition 
to the ~erapeutic advantage offered by 
FK506 treatment. 39 Patients with a pri-
mary liver tumor had the lowest long-
term survival, 72% at one vear and S9% 
at 2 years, similar to that reported in both 
the cyclosporine era40 and the beginning 
of the FKS06 era.41 The most common 
cause of death was recurrence of the pri-
mary tumor, despite the use of adjuvant 
chemotherapy. 
We reported elsewhere the details 
regarding the incidence and treatment of 
rejection episodes in primary OLTx 
patients under FKS06 immunosuppres-
sion.42 However, it should be emphasized 
that the lower incidence of rejection 
with FKS06 was in the face of overall 
lowered corticosteroid use (nearly half of 
the OLTx patients were steroid free by 
100 
~~ 
..... ;IK:~K::~ •••••••••• ! •• 
the third post-transplant month). Other 
aspects of the Pittsburgh experience 
with the use of FKS06 as a primary 
immunosuppressant, like drug toxicity, 
development of opportunistic infections, 
and drug interactions, as well as other 
clinical observations, are published else-
where.43.51 
THREE YEARS EXPERIENCE WITH COMBINED 
LIVER-INTESTINAL AND MULTIVISCERAl 
TRANSPLANTATION 
The first experimental intestinal and 
multi visceral transplantations52 . 54 were 
performed over three decades ago. 
However, for 30 years the intestine was 
considered to be a "forbidden organ" 
because of the high incidence of graft 
loss, either due to technical, immuno-
logical, or infectious complications. 5557 
The demonstration, in clinical liver 
transplantation, of the great efficacy of 
FKS06, and the definition of its role in 
experimental multi visceral transplanta-
tion 58 •59 justified, in 1990, a renewed 
interest in clinical liver-intestinal and 
multivisceral transplantation. 60.61 
PATIENTS AND METHODS 
Our report is based on our experi-
ence with the first consecutive series of 
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patients that underwent transplantation 
of a combined, in continuitv, liver-
intestinal bloc (21 patients): or of a 
multi visceral cluster of abdominal 
organs (8 patients, 2 of whom died dur-
ing surgery, before the organs could be 
implanted). The general term "multi-
visceral transplantation" refers to a class 
of transplants involving the entire small 
bowel, transplanted en-bloc with (,' 
without one or more segments of thl' 
gastrointestinal tract (stomach, duode-
num, or colon), and with or without 
one or more solid upper abdominal 
organs (liver or pancreas). The multi-
visceral transplants reported here 
included liver, pancreas, stomach, duo-
denum, and small bowel. We will limit 
most of our discussion to the 27 
patients that survived the operation. 
There were 11 adults and 16 chil-
dren, transplanted between July 24, 
1990, and April IS, 1993. Most 
patients had end-stage liver diseas< , 
with a mean preoperative serum bilin: 
bin of 19 ± 14 mg/dl. Table IV summa-
rizes the etiologies of the intestinal 
failure and the indications for combined 
liver-intestinal or multivisceral trans-
plantations in this group of patients. All 
donors were ABO identical with the 
recipients, but HLA matching was 
totally random and uniformly poor. The 
lymphocytotoxic crossmatch was posi-
tive in 2 of the 21 combined liver-
intestinal recipients. No attempts were 
made to alter the graft's immunogenici-
ty by manipulating its lymphoreticular 
tissue with anti-lymphocytic immuno-
globulins (ALS, ALG, OKT3), or with 
other immunomodulators (immunosup-
pressive drugs or irradiation) adminis-
tered to the donor or to the graft. The 
details regarding surgical technique 
have been reported elsewhere. 60.62 In 
the present series, all donors were < SO 
years of age (although no age limits have 
been set for intestinal donors, and we 
evaluate every donor for possible 
intestinal donation).6l There were no ." 
non-heart beating donors. 
The extremely complex manage-
ment required by this unique group of 
. h b d' d '1 0465 patIents as een reporte In etal, ' 
FKS06 has been the basic immunosup-
pressant in this clinical series, along 
with steroids and prostaglandin E I • 
Immunosuppressive therapy of ongoing 
acute cellular rejection of multivisceral 
grafts includes the same drugs used for 
induction and maintenance immunosup-
pression (FKS06 and steroids), with the 
occasional addition of monoclonal anti-
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bodies (OKT3). Drug dosage and route 
of administration are adjusted according 
to the severity of the rejection, assessed 
mainly by a histological grading scale. 
Intestinal rejection can impair FK506 
absorption, with resultant inadequate 
trough plasma levels. Consequently, 
optimization of FK506 trough levels, tar-
geting 3-5 ng/ml, should be accom-
plished by either increasing the baseline 
enteral dose or by intravenous supple-
mentation. Adequate and prompt 
immunosuppressive treatment of ongo-
ing acute cellular rejection of multivis-
ceral grafts is usually successful. 
RESULTS 
Patient Survival 
As of June 14, 1994 (18-47 month 
follow-up), 14 out of the original 29 
patients (48.3%) had died. Of the 12 
patients that died after surviving the 
operation, ten had received a combined 
liver-intestine, while two were multi-
visceral recipients. The causes of death 
in the liver-intestine group were either 
technical complications (n=3), oppor-
tunistic infections (n=2), uncontrolled 
graft rejection (n=2), or disseminated 
post transplant lymphoproliferative dis-
ease (n=3). The two postoperative 
deaths in the multivisceral group were 
caused by post transplant lymphoprolif-
erative disease, diagnosed post-
mortem, and sepsis with multiple organ 
failure. Actuarial patient survival was 
72.4%, 65.5%, and 58.6% at 6, 12, 
and 24 months, respectively (Figure 4) . 
Graft Survival 
Figure 5 shows the actuarial graft 
survival for 29 allografts in 27 patients 
(2 patients underwent removal of the 
complete organ block and retransplan-
tation). Graft survival was 70%, 63.3% 
and 56.7% at 6, 12, and 24 months, 
respectively. One graft was lost due to 
lymphoproliferative disease, another 
was lost to rejection (both were liver-
intestine); there were two partial loss-
es: a liver (retransplanted), and a 
pancreas. All other grafts were lost due 
to patient death. 
Immunological Complications 
Rejection. Monitoring of liver-intes-
tine and multivisceral graft rejection is 
based on clinical, endoscopic, 
histopathological, radiological, and 
immunological criteria.64.66-68 Clinical 
criteria are the keystone for early diag-
nosis of acute rejection of the intestinal 
graft. Unlike rejection of other isolated 
solid organ allografts (e.g., heart, lung, 
liver, kidney, pancreas), whose diagno-
sis is mainly made by biopsy and/ or 
functional and laboratory tests, the 
diagnosis of acute intestinal rejection is 
primarily based on clinical criteria, 
which usually present first. Therefore, 
clinical monitoring and careful exami-
nation of the intestinal graft stoma and 
Transplantation 
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its output are essential. Due to disrup-
tion of the normal intestinal mucosal 
barrier, bacterial and/ or fungal translo-
cation can take place, with subsequent 
septic complications and/or ARDS-like 
syndromes. 
Routine endoscopiC surveillance, 
together with multiple selective biop-
sies, are usually performed by terminal 
ileoscopy. although upper endoscopy is 
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al50 sometimes done. They are done 
twice a week for the first month, once a 
week for the next two months, monthlv 
for the next three months, and everv 3'-
6 months, or whenever c1inicallv i~di-
cated, thereafter. ' 
In the present series, the incidence of 
intestinal allograft rejection was much 
higher than that of the liver allografts. In 
fact, whereas 16 patients did not ~have any 
rejection of the liver graft, only 2 (both 
recipients of combined liver-intestinal 
grafts) were free of clinical and histopatho-
logical signs of intestinal rejection. The 
mean postoperative time to the first 
episode was 22 ± 34 days for the com-
bined liver and intestine, and 15 ± 7 davs 
for the multivisceral allografts. On 88 
occasions on which both liver and small 
bowel biopsies were taken simultaneously 
or closely together, 47 (53%) of the dual 
specimens had no signs of rejection in 
either organs, 12 (14%) had rejection in 
both, 15 (17%) had rejection only in the 
Ji\'Cr and 14 (16%) had rejection in the 
intestine only. Chronic rejection was the 
cause of graft failure in one adult, with a 
strong positive cytotoxic crossmatch, who 
received a combined liver-intestine. 
Graft-Versus-Host-Oi sease 
(GVHO) - Monitoring of GVHD is 
done by clinical examination (fever, 
skin rash, septic-like syndrome), 
standard histology, immuno-histochem-
ical techniques (immuno-staining, sex 
identification after fluorescence-in-
situ-hybridization-F1SH) and PCR-kary-
otyping ("DNA fingerprinting"). With 
these procedures it is possible to differ-
entiate migrating immunocompetent 
cells from the donor (donor "passenger 
leukocytes") from recipient cells, as well 
as to document the immunological 
injury of the recipient tissues by the 
infiltrating donor cells. Inadequate 
immunosuppression is a major risk fac-
tor for GVHD. Using standard histology 
and in situ hybridization techniques, 
GVHD was unequivocally diagnosed in 
only one combined liver-intestinal pedi-
atric recipient. Light immunosuppres-
sion was attempted early in the 
postoperative course of this child 
because of pneumocystis carinii pneu-
monia and an intestinal anastomotic 
leak. The skin lesions appeared 10 days 
after transplantation, and the overall 
clinical picture simulated life-threaten-
ing sepsis. The immunosuppression was 
reduced Significantly, and 13 days later 
the patient succumbed to multiple organ 
failure. Therefore, despite of the "his-
torical" fear 65 of high incidence of 
(Children = 16) 
Etiology of Intestinal Failure 
Gastroschisis 
Necro. enterocolitis 
Volvulus 
I ntesti nal atresia 
Microvillus disease 
Pseudo-obstruction 
Etiology of Intestinal Failure 
Crahn's disease 
Abdominal trauma 
Celiac A. occlusion 
S.M.A. thrombosis 
Desmoid tumor 
Metastic gastrinoma 
Budd-Chiari syndrome 
Intestine + liver 
5 
4 
3 
2 
1 
o 
Adults (n = 11) 
Intestine + liver 
. 1 
2 
o 
2 
1 
o 
o 
Multivisceral 
o 
o 
o 
o 
o 
1 
Multivisceral 
o 
a 
3* 
a 
o 
1 
1 
"These patients had short-gut syndrome due to concomitant superior mesenteric artery 
(S.M.A.) thrombosis by Protein S deficiency (n=1), Antithrombin 11/ deficiency (n=1) or 
unknown cause (n=1). 
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GVHD documented in experimental 
intestinal transplantation,54.69-72 our clin-
ical experience has actually shown a 
minimal occurrence of severe GVHO. 
Actually, one of the most intriguing 
findings from the immunological patient 
surveillance was the gradual replace-
ment of the donor hematolymphoid 
cells, in the intestinal wall and mesen-
teric lymph nodes of the graft, b; 
immunocompetent hematolymphoid 
cells of the recipient, which rearrange 
the normal intestinal mucosal immune 
system architecture. 72 Conversely, 
donor migratory immunocytes ("passen-
ger leukocytes") originating from the 
graft migrate at the same time ubiqui-
tously into the recipient blood stream 
and tissues. This new immunological 
status ("systemic chimerism") could be 
the basis of gradual induction of donor 
specific non-reactivity (tolerance). 59.74-76 
The significant advances achieved in 
the field of liver transplantation have 
led to an increased demand for organs, 
and created a wide gap between organ 
availability and supply.63,77 As of March 
31, 1994, there were 34,493 patients in 
the United Network for Organ Sharing 
(UN OS) waiting list,78 up from 13,115 
in December 21, 1987, an increase of 
263%. Of these, 3,264 awaited liver 
transplantation, up from 449 in 1987 
(727% increase). The supply of organ 
donors, on the other hand, underwent a 
marginal increase between 1988 and 
1990 (from 4,085 to 4,514), and has 
remained relatively stable (4,531 in 
1991,4,521 in 1992, and 4,849 in 
1993) thereafter. A wider availability of 
organs for transplantation would allow 
an expansion 79 rather than a contraction 
of the indications for transplantation, 
and at the same time a relaxation of the 
patient selection criteria. 80.81 All these 
facts clearlv justifv the renewed interest 
in xenotra~splantation observed in the 
last decade. 82 
The first three attempts at whole 
organ xenotransplantation were made in 
France and Germany between jan'Jary 
and April 1906, using a pig, a ~oatI and 
a macaque as kidney donors.8 ,84 None 
of these kidnevs functioned because of 
almost immediate vascular thrombosis, 
and the human recipients died in less 
than 3 days. In a further attempt in 1923 
by Neuhof1l5 a lamb was used as a kidney 
d~norI and the patient died 9 days after. 
On February 16, 1963, Hitchcock of 
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the Hennepin County Hospital, in 
Minneapolis, transplanted the kidney of 
a baboon to a 65-vear-old woman. The 
organ functioned 'for 4 days before its 
arterv clotted. ~b A few months later on 
Octoher 8, 1963, Reemtsma of Tulane 
Universitv used a Rhesus monkev as kid-
ney don~r for a human recipi~nt who 
survived 12 davs. Then, Reemtsma tried 
again with a 'series of 6 consecutive 
chimpanzee kidney grafts. 87 One of 
these xenografts functioned for 270 
days. 
• In December, 1963 and January, 
1964, 6 patients received baboon kid-
nevs at the University of Colorado, in 
a~nverK 88 All of thes~ kidnevs worked 
immediately and sustained ~ dialysis-
free life for 10 to 60 days. The patients 
were treated with high doses of azathio-
prine and prednisone, and 4 of them 
died of sepsis, while rejection was 
mainly responsible for the other two 
deaths. However, the pathology of the 
rejection was not qualitatively different 
from that observed in allografts. go 
Similar immunopathological events 
brought to failure, after 20 days, a 
baboon heart transplanted in 1984 into 
a 2.2 kg neonate,90 in spite of heavy 
cyclosporine-steroid immunosuppres-
sion. A pig kidney and heart transplant-
ed by KUSS91 and ROSS,9! respectively, in 
the 1960s were hyperacutely rejected in 
a matter of minutes, demonstrating that 
the pig was not, and will not be, an easy 
donor for a human recipient. 
The Antiproliferative Drugs -
Sir Peter Medawar, in 1969, stated that: 
"A new solution is therefore called for: 
the use of heterografts - that is to say, of 
grafts transplanted from lower animals 
into man. Of the use ofheterografts I can 
say only this: that in the laboratory we 
are achieving greater success with grafts 
between species today than we achieved 
with grafts within 15 years ago. We shall 
solve the problem by using heterografts 
one day if we try hard enough, and 
mavbe in less than 15 vears".93 However, 
the'laboratory work p~rformed at differ-
'nt institutions in the following 15-20 
cars did not bring results that could 
encourage further clinical trials. In May, 
1992 a study performed in Pittsburgh by 
M urase et a1., 94 using a hamster -to-rat 
xenotransplant model, was discussed at 
the meeting of the American Society of 
Transplant Surgeons, in Chicago. 
Murase's work clearlv showed that indef-
inite survival under FK506 was routinelv 
achievable if it was combined, for th~ 
first two post-transplant weeks, with 
either of two "antiproliferative" drugs 
that suppress purine (RS 61443) or 
pyrimidine (brequinar) ribonucleotide 
synthesis. The use of cyclophosphamide, 
an alkylating a~ent with considerable B 
cell specificity,3 .95 allowed similar consis-
tent chronic survival after either heart or 
liver xenotransplantation. Particularly 
Significant was the fact that a Single large 
dose of cyclophosphamide, given 10 days 
before the xenotransplant, allowed suc-
cess in almost 100% of the animals with 
onlv dailv administration of FK506. This 
wo~kI together with the previous experi-
ence with cyclophosphamide96 ,97 as an 
effective drug in clinical transplantation, 
justified its use in clinical xenograft tri-
als. 
The Liver Clinical Xeno-
transplant Trial - On June 28, 
1992, and on January 10, 1993, t\\'O 
patients, age 35 and 62 years, respec-
tively, underwent liver xenotransplanta-
tion. Both had end-stage chronic active 
hepatitis caused by hepatitis B virus 
(HBV), and were in stage 3 coma dur-
ing the 24 hours that preceded the 
surgery. The evidence that the baboon 
lh'er is resistant to the HBY,98.99 which 
reinfects most allografts under compa-
rable circumstance, lOa prompted the 
selection of these two candidates, to 
whom human liver transplantation had 
already been refused at other institu-
tions. The second patient was far more 
T",,,.I,,,,radofl 
SURGICAL TECHNOLOGY I/IITERNATIONAL III 
frail, and underwent splenectomy on 
the fourth day post-transplant. y~hiltD 
the first had had a splenectomy (for 
trauma) in 1989. Both patients' were 
immunocompetent at the time of tht, 
xeno~raftI althou&h the first also had an 
HIV mfectlOn. 98 , 9.101·IOl These differ-
ences may have impacted on the eflicacv 
of the perioperative immune modula"-
tion. 
The chosen donor animal was the 
baboon Papio cynocephalus. The techni-
cal details of the donor surveillance and 
selection, as well as of the donor and 
recipient operations, have been pub-
lished elsewhere98 ,99.101.I03 and will not 
be repeated here. The baboon liver 
reperfused promptly and uniformly in 
both cases (Figure 6). The post-reperfu-
sion biopsies showed a good liver archi-
tecture, with a moderate degree of 
sinusoidal neutrophilic aggregates. The 
immunosuppression was based on the 
use of 4 drugs: cyclophosphamide, 
FK506, methylprednisolone and PGE,. 
Doses and routes of administration are 
shown in Figures 7 and 8. Cyclopho-
sphamide was started 2 days before the 
xenotransplants, and was given for 56 
days (out of 70) in Case 1, and for 10 
da~s (out of 26) in Case 2, with the dose 
ra~ging from 0.07 to 10.6 mg/kg/ day. 
FK506 was started on the day of the 
xenografts and, except for higher doses 
given during the first 2 postoperative 
weeks in Case 1, the doses were within 
standard therapeutic ranges. Detailed 
fllure 6: The Paplo c:ynocephaIus liver at tfIe tne of re.-fusion In tfIe bllboon-.... lllllln liver XIIIICIInnI· 
plantation (first patient: June 28, 19921. The organ Is unIfonnIy and nicely reperfused. (From: Marino II, 
Tukia AG, Fung JJ, Tedo S, Doyle HR, MaRl R, Starzl T£. LIver xenotranaplantatlon. In: SurP:a1 
Tec:hnoIo&Y 1 ..... 1IIIIiaI181 II, IIrInmI8n MH and T_ Ill. (.1, 139-144, 1homIIs F. Laszlo ......... 
San Francisco, Callfamla, 1993. Used by JIMlI .... l. 
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descriptions of the immunosuppressive 
drug doses and their blood levels have 
been recently reported else-
where. 98,99,IOI.103 The first patient awoke 
promptly, was extubated after 17 hours, 
and was eating and walking 5 days after 
surgery. He had an almost normal biliru-
bin for the majority of the 70 days that 
he survived (Figure 7). He also spent 
more than 30 days in a regular ward. 
The second patient, however, remained 
icteric (Figure 8) and comatose, and 
required mechanical ventilation during 
his whole postoperative course. Both 
patients suffered from hypoalbumine· 
mia, and received frequent albumin infu-
sions.98.99.101-103 The first patient went 
into renal failure on postoperative day 
2 1, while the second patient became 
anuric immediately after surgery. 
I.V. 
Papio cynocephalus normally pro· 
duces elevated levels of factor VIl and 
low levels of factors IX and XI, as com-
pared to humans. Coagulation profiles 
were done in both recipients preopera-
tively and several times postoperatively. 
Our results, reported elsewhere,104 
showed that the baboon's coagulation 
pattern was acquired by the ~patient 
after liver xenografting, but this did not 
affect the clotting ability of the patients. 
During their postoperative course, 
the patients underwent several liver 
biopsies (6 in patient 1 and 8 in patient 
2, including the autopsy speCimens). 
Only the biopsy obtained from the tlrst 
patient on the 12th postoperative day 
had signs of mild focal cellular rejection, 
while no evidence of cellular rejection 
was detected in any of the other biopsies 
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from either patient.98.99.101.IOl.IO; No evi-
dence of HBV reinfection was 
detectable b~D immunoperoxidase stain-
ing in the liver tissue at any time. 
Both baboon livers underwent a dra-
matic growth after implantation into the 
larger human recipient, with tripling or 
quadrupling of the organ volume within 
the first month.102 The cause of death in 
the first case was diffuse subarachnoid 
hemorrhage and left uncal brain stem her-
niation, secondary to angioinvasive 
aspergillosis; the second patient died of 
peritonitis. Details of the necropsies have 
been reported elsewhere. 98,99, 101·103 
However, cell chimerism was proven in 
both patients by the presence of baboon 
DNA in all tissues examined (using PCR 
amplification of baboon-specific 
DNA).98.99 It should also be noted that, in 
addition to the liver, the second patient 
was given a large dose of baboon bone 
marrow cells (3 x 1 081 Kg body weight), 
after the reperfusion of the baboon liver. 
Analysis of the Two Cases and 
Strategies for Future Clinical 
Xenotransplantation. - The most 
disquieting fact in our baboon-to-
human liver transplant experience was 
the disparity between the paucity of the 
histopathologic findings of rejection 
(which was very encouraging) and the 
discouraging functional deficiencies of 
these xenotransplants, which suggested 
incomplete control of xenograft rejec-
tion. The pathology of the transplanted 
baboon livers was compared to that of 6 
baboon kidne~D xenorafts transplanted 
in Denver in 1963. 8 .89 These kidneys, 
as we mentioned before, functioned for 
6 to 60 days. The key pathological find-
ing was an occlusive endothelialitis of 1 
the graft vessels, presumably antibody-
mediated. The patholol?:Y of those kid-
nevs removed in 1964r9 showed distal 
ischemia, caused by the vascular injury, 
that appeared to be responsible for the 
patchy gangrene of the xenografts. In 
the two recent liver xenotransplants, 
polymorphonuclear leukocytes were 
seen in the sinusoids immediatelv after 
reperfusion, and biliary sludgi~g was 
detected at the autopsy. Both the sludg-
ing and the appearance of polymor-
phonuclear leukocytes were compatible 
with a diagnosis of an aborted hypera-
cute (humoral) rejection. Complement 
studies were also consistent with this 
pOSSibility. Total complement was 
depleted for most of the critical fIrst 2 
weeks, while complement components 
C3, 4 and 5 became undetectable. 
J 
/ 
r 
a 
a 
n 
tl 
a 
n 
si 
11 
d 
\, 
n 
b, 
S\ 
al 
ta 
Xl 
g( 
al 
Ii, 
I-
:s 
I-
l-
Ie 
n 
n 
.n 
R 
iC 
ill 
It 
Ie 
I, 
d 
II 
5t 
)-
as 
Ie 
>n 
Ie 
of 
~d 
c-
~d 
6 
d 
s, 
)r 
d-
of 
y-
d-
cal 
~yI 
he 
In 
ts, 
re 
er 
as 
(1-
D 
r-
lie 
ra-
~nt 
his 
'as 
t 2 
nts 
Ie. 
, 
During this time, circulating immune 
complexes appeared. 99. 101 After 10 days 
the complement system was restored, 
but irreversible damage may have been 
already done. Although these baboon 
liver xenografts looked almost normal, 
closer inspection showed a very fine 
microsteatosis, which was particularly 
obvious in the second patient. This may 
represent a sub-lethal immunological 
injury that precluded long term success 
in both cases. 
We believe now that these livers 
were acutely damaged by an incomplete 
version of a form of rejection that was 
described, in 1964, in ABO incompati-
ble kidneys,I06.107 and seen later in kid-
ney allografts transplanted across a 
positive lymphocytotoxic crossmatch. 108 
These were the first descriptions of 
hyperacute kidney rejection by pre-
formed antigraft antibodies. A few 
years later, hyperacute kidney rejection 
was defined in a more sophisticated way 
as a complement activation syndrome, 
analogous to the Shwartzman and local 
Arthus reactions. 109.110 It was pointed 
out that, although hyperacute allograft 
rejection usually was associated with 
antigraft antibodies, this was not an 
absolute requirement, a heretical state-
ment at that time. However, the distinc-
tion between hyperacute rejection with 
and without preformed antibodies is 
merely the difference between the clas-
sical pathway of complement activation, 
in which the first steps are antibody 
dependent, and the alternative pathway, 
which does not require an antibody 
trigger or the participation of comple-
ment components CI, C2, and C4. We 
believe that these hyperacute rejection 
syndromes, \\ith or without preformed 
antigraft antibodies, are not fundamen-
tally different from those seen after 
xenotransplantation of organs between 
genetically diverse species. 
Many methods of manipulating the 
xenograft recipient have been tried and 
re-tried since the 1960s, without any 
defInite success. These methods include 
antibody suppression, III antibody deple-
tion,112.123 inhibition of the complement 
cascade, 1241,9 and inhibition of the 
inflammatory response. 130·131 Alteration 
of the xenograft before its implantation, 
mainly by blocking antibody binding sites 
with recipient F (ab')2 immunoglobulin 
fragments,110.l12.1B has also been unsuc-
cessful. The introduction of the concept 
of systemic chimerism, has heightened 
interest in designing strategies aimed to 
alter the cell composition of the graft. 
The creation of a transgenic pig, to 
be utilized as a source of organs for 
clinical xenotransplants, has been 
already started in a few laborato-
ries.134.13S The scientists working on this 
project have embarked on a program to 
produce pigs transgenic for human reg-
ulators of complement activation (e.g. 
OAF, C059, and Mep). This is 
achieved by micro-injection of human 
genomic ON A fragments into the 
pronuclei of fertilized porcine 
oocytes. 136 However, only one of the 
components of the xenotransplant bar-
rier could be overcome by this strategy 
(namely, the complement cascade); 
therefore it is difficult to hope that a 
complete control of rejection will be 
achieved by this method alone. 
One other extremely fascinating 
possibility is the production of chimeric 
I.V. 
Transplantation 
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organs. Human-to-baboon bone mar-
row transplantation has alreadv been 
performed in our laboratorie;, after 
conditioning with non-lethal irradia-
tion. ll7 In this experiment, two 
baboons preconditioned with 7.5 Gv 
total lymphoid irradiation were give~ 
6x 1 0 8 / Kg body weight unaltered 
human bone marrow cells, without any 
subsequent treatment. Donor DNA was 
found Widely distributed in the tissues 
of both animal when they were sacri-
fked, 18 months later. It'is also inter-
esting to note that GVHO did not occur 
in either animal. As recentlv stated else-
where 105: "it remains t~ be seen if 
incomplete or even full chimerism will 
change the image of baboon organs 
enough to make them viewed as allo-
grafts by humans". In conclusion, the 
impression we want to leave is that with 
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a combination of modern immunosup-
pressive agents and donor cell manipu-
lation the prospect of successfull)' 
performing clinical xenografts seems 
today closer than ever, 
INDUCTION OF GRAFT ACCEPTANCE 
The mechanisms through which allo-
grafts are able to weather the initial 
~ecipient immune system attack, and 
later allow for two cell populations 
(donor and recipient) to coexist with 
less and less need for immunosuppres-
sion, was not well understood until 
recently. It has been postulated by 
us 74,75.138,139 that the migration of donor 
leukocytes from transplanted organs, 
facilitated by immunosuppressive drugs, 
and the ubiquitous persistence of these 
cells in the recipient tissues, are the 
seminal explanation for the occurrence 
of microchimerism. Also, this cell 
migration is the first stage in the devel-
opment of donor speCific nonreactivity, 
and the necessary pathway to allograft 
acceptance. 
Observations compatible with this 
concept were already reported more 
than 30 years ago, when azathioprine 
and prednisone were introduced as 
combined immunosuppression for kid-
ney transplantation. 14O In fact, there is a 
characteristic cycle of kidney allograft 
rejection, in the first few days or weeks 
post transplant, that can be reversed 
GVH 
with steroids. The abilitv to reduce and 
sometimes even to stop the immuno-
suppression was thereafter confirmed in 
cases of transplantation of the liver, 
heart and other solid organs. More 
recently, study of transplanted abdomi-
nal organs and their host have provided 
unique inSights into these process-
es. 74.75 ,138.139,141,142 In 1969 it was noted 
that the Kupffer cells and other tissue 
leukocytes became predominantly of 
recipient phenotype within 100 days of 
transplantation, while the hepatocytes 
permanently retained their donor speci-
fiCity. This transformation was long 
assumed to be unique to the hepatic 
allograft. 143 
However, 22 years later, first in rat 
models, and then in humans, it was 
realized that the same process occurred 
in all successfully transplanted intestines 
(see previous section), and other 
organs, differing quantitatiyely (and 
perhaps qualitatively) in the number of 
substituted tissue leukocytes, being 
greatest with the liver. In 1992,144 the 
fate of the leukocytes vacating the grafts 
was determined by studying the longest 
survivors after kidney (30 years) or 
liver transplantation (23 years). 
Biopsies were obtained from these 
patients, and from more recently trans-
planted patients that received hearts, 
lung, or intestines. Samples were taken 
from the transplanted organ, as well as 
from the patient's own skin, lymph 
Mutual natural 
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nodes, and other tissues. After special 
staining procedures (immunostaining or 
sex identification after fluorescence in 
situ hybridization [FISH)), it was possi-
ble to determine if the individual cells 
had come from the donor organ, the 
recipient's own body, or both. In con-
firmatory investigations, the donor and 
recipient contributions to any specimen 
could be separated by polymerase chain 
reaction ("DNA fingerprinting") tech-
niques. 
From these analyses, supporting lab-
oratory experiments in animals, and the 
most recent experience with baboon-
to-human transplants, it became clear 
that within minutes after restoring the 
blood supply of any transplant, myriads 
of sessile, but potentially migratory 
leukocytes that are part of the normal 
structure of all organs (passenger leuko-
cytes) left the allograft or the xenograft 
and migrated ubiquitously; at the same 
time they were being replaced in the 
transplanted organ by similar recipient 
immunocytes, under the protection 01 
immunosuppressive drugs (ure 9). In 
this new context, the drugs could be 
viewed as traffic directors, allowing 
movement of leukocvtes to and from 
the allograft or the x~nograftI but pre-
venting the immune destruction that is 
the normal purpose of this traffic. 
Because of this bidirectional cell traffic, 
an immunological status can be reached 
in which immunosuppression can be 
stopped, particularly after liver trans-
plantation. 145 Such a stable immunolog-
ical condition can be achieved marl" 
easilv with the liver than with any othe: 
graft, because of the high conce~tration 
in the liver of those critical leukocytes 
that apparently include pluri-potent 
stem cells. 
PATIENTS AND METHODS 
In a direct extension of this 
described leukocyte chimerism that 
occurs spontaneou~ly with whole organ 
allo- and xenotransplantation, we aug-
mented the host leukocyte load by peri-
operative infusion of unmodified donor 
bone marrow to 36 organ recipier:s 
who were treated with a conventional 
regimen of FK506 and prednisone 
immunosuppression. We report herein 
only on the first 18 patients, treated 
between December 1992 and 
December 1993, and for whom a fol-
low-up of 4 to 16 months is available. 
Ten patients received a kidney trans-
'I I 
plant, 7 received a liver, and 1 received 
a heart, including 3 diabetics with no 
detectable serum C-peptide who also 
received pancreatic islets intraportally. 
Their mean age was 46 ± 13.2 years, 
(range 20 to 63 ). The cadaveric donors 
were ABO identical with their recipi-
ents, and all patients received 3x 1 l~ 
donor bone marrow cells/Kg of recipi-
ent body weight, at the time of the solid 
organ graft. 
RESULTS 
All patients are presently well, and 
have excellent function of their trans-
planted organs. Persistent multilineage 
leukocyte chimerism was found in the 
blood of 17 of these 18 recipients, using 
either flow cytometry and qualitative or 
quantitative PCR techniques for detec-
tion of donor HLA alleles or, addition-
allY, Y chromosomes in female 
re~ipients of male organs. In the only 
patient in whom chimerism could not 
be demonstrated, the use of as-antigen 
HLA matched, same-sex donor pre-
cluded the use of these markers. 
Rejection was diagnosed and successful-
ly treated in 9 (50%) of the 18 recipi-
ents' and transient GVHD occurred in 
2 (11 %). Donor specific hyporeactivity 
at variable times postoperatively was 
demonstrable with in vitro tests in the 
majority of the recipients, and could be 
identified as earlv as 50 davs post-trans-
plant. It is now t~o early t~ attempt dis-
continuation of the immunosuppressive 
therapy, however, the pronounced trend 
to donor-specific nonreactivity (toler-
ance) revealed by the in vitro tests is 
very encouraging. 
CONCLUSIONS 
During the last 15 years, survival 
after orthotopic liver transplantation 
has dramatically improved. This has 
been due to advanced medical technol-
ogy, and important technical refine-
ments,7.9 better organ preservation, 146 
and new potent immunosuppressive 
drugs. 5.147 The recent introduction of 
FK506 has further improved the sur-
\'ivai and the quality of life of liver 
transplant recipients, compared with 
our previous experience. 147 Summary of 
the worldwide experience with FK506 
was presented during the 1991 First 
International Congress on FK506, and 
has been published elsewhere. 148 FK506 
completed on April 8, 1994, its "fast 
track" journey through the Food and 
Transplantation 
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Drug Administration, and it is no\\' 
com;nercialIv available in the U.S. 
The rece~t achievement of satisfac-
tory long term survival of patients 
treated with combined liver-intestinal 
and multivisceral transplantation justi-
fies a continuation of the clinical trials. 
However, the surveillance and intensitv 
of care required by these patients fo'r 
the first year, and in most instances 
thereafter, was very high, far more than 
at comparable times after the transplan-
tation of the liver alone. Further 
immunologic and surgical strategies 
will be required to increase the practi-
calitv and success of such creative 
surge'r),.65 
Although our recent attempts at 
baboon-to-human xenotransplantation 
failed, there were encouraging nota-
tions. First, the xenografts had no evi-
dence of B virus infection during their 
post-transplant survival of 70 and 26 
days in B virus carriers. Second, there 
al:o was little histopathologic evidence 
of humoral or cellular rejection of both 
IiYer xenografts. Nonetheless, the func-
tion of both xenografts was unsatisfac-
tory. This could be explained by a 
damage caused by a complement activa-
tion syndrome precipitated by classical 
pathway or independent of antibodies 
(alternative pathway). Third, the dis-
covery that chimerism easily occurs 
after baboon-to-human transplants, and 
after human-to-baboon bone marrow 
transplant, can possibly open new 
avenues for the feasibility of clinical 
xenotransplantation. 
The discovery that immunosuppres-
sive drugs can lead to tolerance induc-
tion, by allOWing a previously 
unrecognized common mechanism of 
cell migration and micro chimerism to 
occur, has important therapeutic and 
clinical implications. 
Because the chimeric leukocytes dis-
persed from the allograft are 'of bone 
marrow origin, a therapeutic corollary 
was that acceptance of less favored 
organs such as the heart and kidney (or 
even the liver itself) could be facilitated 
bv the infusion of unaltered donor bone 
~arrow perioperatively. Donor leuko-
cvte infusion to induce tolerance was 
the best therapeutic strategy of trans-
plantation immunology, but perhaps the 
least well understood. It was first used 
bv Main and Prehn 149 who showed that 
f~thally irradiated adult mice reconsti-
tuted with allogeneiC bone marrow 
could accept skin from the same donor 
strain but no other. These were efforts 
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to mimic the two conditions (inocula-
tion of mature donor immunocvtes and 
immunologic non-reactivity of recipi-
ents) that had allowed Billingham, Brent 
and Medawar lso to induce acquired tol-
erance of neonatally or pcrinatall~D 
injected mice. Thousands of similar 
experiments, as well as the treatment 
policies in the clinical field of bone 
marrow transplantation, have assumed 
the need for either a natural or imposed 
state of host non-reactivity. The resul-
tant risk of GVIID from·liYcr donor 
cells, described hv Billingham and 
151 • Brent, has been so great in the pres-
ence of MHC incompatibility that their 
use has been largely avoided. 
Armed with the discoveries that nat-
ural chimerism from the graft itscl f 
begins within minutes of organ revascu-
larization, and is persistent, it was pos-
sible during 1993 to simulate this 
timing in unconditioned patients whose 
transplanted organ, routine immuno-
suppression, and adjuvant bone marrow 
all arrived peri operatively. The ambi-
tious goal of these projects is to induce 
a condition of donor-specific tolerance, 
both in allo- and xenotransplantation, 
preserving all the functions of the host 
immune system. These achievements, 
along with the demonstration that 
xenotransplantation and intestinal 
transplantation are a clinical possibility 
and not any longer futuristic projects, 
will be chronicled as some of the most 
significant advances in medicine. When 
all these become a reality the work 
started bv Sir Peter Meda~ar will be 
completed. m:J 
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